hdm201
Hdm201 is a drug used to treat AML, Adult, Acute Myeloid Leukemia (AML), Advanced Cancer, and other conditions. Hdm201 is being actively studied in 5 studies and prior, has been studied in 3.
| Top Sponsors | Top Sites | Top Investigators |
|---|---|---|
| Novartis Pharmaceuticals | Novartis Investigative Site | |
| Centre Leon Berard | Centre Leon Berard | |
| University Hospital Inselspital, Berne | Centre Antoine LACASSAGNE |
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
U
Recruiting
- AML, Adult
- HDM201
- Midostaurin
- Berne, SwitzerlandDepartement of Medical Oncology, University Hospital Berne
2022-01-27
Jan 27, 2022C
Not yet recruiting
- Advanced Soft-tissue Sarcoma
- Metastatic Soft-tissue Sarcoma
- Pazopanib
- HDM201
- (no location specified)
2021-12-20
Dec 20, 2021C
Recruiting
- Colorectal Cancer
- +2 more
- HDM201
- Trametinib
- Lyon, FranceCentre Leon Berard
2021-07-09
Jul 9, 2021N
Recruiting
- Acute Myeloid Leukemia (AML)
- High-risk Myelodysplastic Syndrome (MDS)
- HDM201
- +2 more
- Durham, North Carolina
- +9 more
2022-03-23
Mar 23, 2022N
N
Completed
- Advanced Solid and Hematological TP53wt Tumors
- HDM201
- ancillary treatment
- Boston, Massachusetts
- +14 more
2021-05-20
May 20, 2021N
Withdrawn
- Leukemia, Myeloid, Acute
- HDM201
- +6 more
- (no location specified)
2020-01-06
Jan 6, 2020C
Recruiting
- Malignant Solid Tumor
- HDM201
- +3 more
- Bordeaux, France
- +5 more
2022-03-23
Mar 23, 2022N
Completed
- Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma
- PDR001
- +5 more
- Santa Monica, California
- +24 more
2022-03-11
Mar 11, 2022